Qiagen (QGEN) has partnered with ID Solutions to improve access to advanced genetic testing tools for cancer research.
The collaboration combines global expertise, automation and manufacturing capabilities to expand the availability of digital polymerase chain reaction tests, which help analyze DNA for scientific studies, Qiagen said Thursday in a statement.
As part of the agreement, ID Solutions of France will develop and supply these digital PCR tests for non-clinical research use on Qiagen's QIAcuity platforms.
Qiagen of the Netherlands plans to commercialize the assay kits in Europe initially with possible expansion into other markets.
Financial details of the collaboration weren't disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.